financetom
Business
financetom
/
Business
/
Orla Mining's Q2 Adjusted Earnings, Revenue Increase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Orla Mining's Q2 Adjusted Earnings, Revenue Increase
Aug 12, 2025 2:06 AM

04:38 AM EDT, 08/12/2025 (MT Newswires) -- Orla Mining ( ORLA ) reported Q2 adjusted earnings Monday of $0.20 per share, up from $0.07 a year earlier.

Analysts polled by FactSet expected $0.20.

Revenue for the quarter ended June 30 was $263.7 million, compared with $84.6 million a year earlier.

One analyst polled by FactSet expected $269 million.

Shares of Orla Mining ( ORLA ) were up more than 2% in recent premarket activity Tuesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
InspireMD Q3 revenue beats estimates on commercial launch of CGuard Prime
InspireMD Q3 revenue beats estimates on commercial launch of CGuard Prime
Nov 4, 2025
Overview * InspireMD ( NSPR ) Q3 revenue grows 39% yr/yr, beating analyst expectations * Net income for Q3 beats analyst estimates despite larger net loss * Company attributes revenue growth to U.S. launch and international market penetration Outlook * InspireMD ( NSPR ) highlights strong demand for its CGuard Prime globally * Company emphasizes strategic focus on U.S. commercial...
Sotera Health beats Q3 estimates, raises FY profit guidance
Sotera Health beats Q3 estimates, raises FY profit guidance
Nov 4, 2025
Overview * Sotera Health ( SHC ) Q3 revenue rose 9.1% to $311 mln, beating analyst expectations * Adjusted EPS for Q3 increased to $0.26, surpassing analyst estimates * Adjusted EBITDA for Q3 rose 12.2% to $164 mln, exceeding expectations Outlook * Sotera Health ( SHC ) raises 2025 Adjusted EBITDA growth range to 6.75%-7.75% * Company reaffirms 2025 net...
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
Nov 4, 2025
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc ( RPRX ) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam, in which Blackstone invested to support AMVUTTRA’s...
Neuronetics Q3 revenue misses estimates
Neuronetics Q3 revenue misses estimates
Nov 4, 2025
Overview * Neuronetics Q3 2025 revenue rose 101% yr/yr but missed analyst expectations * U.S. Greenbrook clinic revenue grew 25% on an adjusted pro forma basis * CEO Keith J. Sullivan to retire in June 2026, search for successor underway Outlook * Company expects Q4 2025 revenue between $40 mln and $43 mln * Neuronetics ( STIM ) revises 2025...
Copyright 2023-2026 - www.financetom.com All Rights Reserved